CLYMClimb Bio, Inc.

$522M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$7M

Net Income

-$19M

EPS (Diluted)

$-1.69

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$297,000

Balance Sheet

Total Assets

$54M

Total Liabilities

$4M

Stockholders' Equity

$50M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$7M	-$2M	-252.6%
Net Income	-$19M	-$2M	-870.8%

CLYM Q1 2021 Earnings — Climb Bio, Inc. Revenue & Financial Results | Market Cap Arena